Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 7/20 | 0.64 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.64 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.64 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BHMT | Q93088 | 1/20 | 0.44 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229136 | 1.00 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL839403 | 1.00 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL18229129 | 1.00 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL3991878 | 0.98 | SLC1A2 (0.62) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL28460968 | 0.98 | SLC1A2 (0.62) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL5612600 | 0.98 | SLC1A2 (0.62) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL3999984 | 0.98 | SLC1A2 (0.62) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL28900373 | 0.88 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL28900372 | 0.88 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL28900379 | 0.86 | SLC1A2 (0.68) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112312968-A | Crystalline salts of 5-methyl- (6S) -tetrahydrofolic acid and ethyl L-leucine | 默克专利股份有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-119097618-A | Leucine, acetylleucine and related analogues for the treatment of diseases | 内在生物技术有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-114040757-B | Leucine, acetylleucine and related analogues for the treatment of diseases | 内在生物技术有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-3364958-B1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4112611-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-114040757-A | Leucine, acetylleucine and related analogs for the treatment of disease | 内在生物技术有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| CN-101426505-A | Dihydrothienopyrimidine for treating inflammatory disorders | BOEHRINGER INGELHEIM INT (DE) | 2009-05-06 | — | — | CN | disclosed |
| EP-2038266-A2 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Abbott Laboratories (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007140385-A2 | THIAZOLE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| CN-1211188-A | Urogenital and intestinal compositions | PROCTER & GAMBLE (US) | 1999-03-17 | — | — | CN | disclosed |
| CN-1211189-A | Urogenital and intestinal disorder compositions comprising a substrance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor | PROCTER & GAMBLE (US) | 1999-03-17 | — | — | CN | disclosed |
| EP-0881905-A1 | UROGENITAL AND INTESTINAL DISORDER COMPOSITIONS COMPRISING A SUBSTANCE DERIVED FROM PLANT SPECIES OF THE ERICACEAE FAMILY AND A LACTIC ACID BACTERIA GROWTH FACTOR | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0880354-A1 | UROGENITAL AND INTESTINAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029762-A1 | UROGENITAL AND INTESTINAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997029763-A1 | UROGENITAL AND INTESTINAL DISORDER COMPOSITIONS COMPRISING A SUBSTANCE DERIVED FROM PLANT SPECIES OF THE ERICACEAE FAMILY AND A LACTIC ACID BACTERIA GROWTH FACTOR | THE PROCTER & GAMBLE COMPANY (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC1A2 138/4885SLC1A1 289/4885SLC1A3 219/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC1A2 138/4885SLC1A1 289/4885SLC1A3 219/4885 |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC1A2 138/4885SLC1A1 289/4885SLC1A3 219/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | SLC1A2 690/4885SLC1A1 548/4885SLC1A3 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.